1,720,959 research outputs found
Livedo racemosa: A striking dermatological sign for the antiphospholipid syndrome
No full text[No abstract available]Amengual O, 2003, RHEUMATOLOGY, V42, P1029, DOI 10.1093-rheumatology-keg273; Asherson RA, 2006, CLIN EXP RHEUMATOL, V24, pS46; ASHERSON RA, 1989, BRIT J DERMATOL, V120, P215; BAGULEY E, 1988, ANN RHEUM DIS, V47, P702, DOI 10.1136-ard.47.8.702; Cervera R, 2002, ARTHRITIS RHEUM, V46, P1019, DOI 10.1002-art.10187; CHAMPION RH, 1960, P ROY SOC MED, V53, P961; DEVOS J, 1992, DERMATOLOGY, V185, P296; Ehrmann S, 1907, WIEN MED WOCHENSCHR, V57, P777; ENGLERT HJ, 1989, AM J MED, V87, P408; Frances C, 1999, MEDICINE, V78, P209, DOI 10.1097-00005792-199907000-00001; Frances C, 2005, ARTHRITIS RHEUM, V52, P1785, DOI 10.1002-art.21041; Frances C, 2000, J AUTOIMMUN, V15, P139, DOI 10.1006-jaut.2000.0418; Gibbs MB, 2005, J AM ACAD DERMATOL, V52, P1009, DOI 10.1016-j.jaad.2004.11.051; HUGHES GRV, 1984, CLIN EXP DERMATOL, V9, P535, DOI 10.1111-j.1365-2230.1984.tb00856.x; Hughes GRV, 1999, ISRAEL MED ASSOC J, V1, P100; HUGHES GRV, 1983, BRIT MED J, V287, P1088; Hughes GRV, 2003, ANN RHEUM DIS, V62, P1127, DOI 10.1136-ard.2003.006163; KALASHNIKOVA LA, 1990, NEUROLOGY, V40, P464; Karassa FB, 2000, QJM-MON J ASSOC PHYS, V93, P169, DOI 10.1093-qjmed-93.3.169; KESTER S, 1992, ANN EMERG MED, V21, P207, DOI 10.1016-S0196-0644(05)80168-4; Khamashta MA, 2000, J AUTOIMMUN, V15, P249, DOI 10.1006-jaut.2000.0421; Kraemer M, 2005, J NEUROL, V252, P1155, DOI 10.1007-s00415-005-0967-9; LEVINE SR, 1988, NEUROLOGY, V38, P798; Lopez-Pedrera C, 2006, ARTHRITIS RHEUM, V54, P301, DOI 10.1002-art.21549; LUBACH D, 1990, J AM ACAD DERMATOL, V22, P633, DOI 10.1016-0190-9622(90)70087-X; MCHUGH NJ, 1988, ANN RHEUM DIS, V47, P110, DOI 10.1136-ard.47.2.110; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111-j.1538-7836.2006.01753.x; Piette WW, 2000, BRIT J DERMATOL, V142, P1080, DOI 10.1046-j.1365-2133.2000.03590.x; Sangle S, 2005, ANN RHEUM DIS, V64, P147, DOI 10.1136-ard.2004.020743; Sangle SR, 2003, ANN RHEUM DIS, V62, P999, DOI 10.1136-ard.62.10.999; Sangle SR, 2005, RHEUMATOLOGY, V44, P372, DOI 10.1093-rheumatolgy-keh490; Sepp N., 2003, DERMATOLOGY, P1651; SEPP N, 1995, AM J SURG PATHOL, V19, P448, DOI 10.1097-00000478-199504000-00006; SHEALY CN, 1970, J AMER MED ASSOC, V212, P1522; SNEDDON IB, 1965, BRIT J DERMATOL, V77, P180, DOI 10.1111-j.1365-2133.1965.tb14628.x; Tietjen GE, 2002, HEADACHE, V42, P352, DOI 10.1046-j.1526-4610.2002.02106.x; Toubi E, 2005, CLIN EXP RHEUMATOL, V23, P499; WEINSTEIN C, 1987, ARCH DERMATOL, V123, P596, DOI 10.1001-archderm.123.5.596; WEST SG, 1995, AM J MED, V99, P153, DOI 10.1016-S0002-9343(99)80135-1; Wohlrab J, 2001, BRIT J DERMATOL, V145, P285, DOI 10.1046-j.1365-2133.2001.04348.x; ZELGER B, 1993, ARCH DERMATOL, V129, P437, DOI 10.1001-archderm.129.4.437; ZELGER B, 1992, HUM PATHOL, V23, P668, DOI 10.1016-0046-8177(92)90323-U40292
Livedo racemosa: A striking dermatological sign for the antiphospholipid syndrome
No full text[No abstract available]Amengual O, 2003, RHEUMATOLOGY, V42, P1029, DOI 10.1093-rheumatology-keg273; Asherson RA, 2006, CLIN EXP RHEUMATOL, V24, pS46; ASHERSON RA, 1989, BRIT J DERMATOL, V120, P215; BAGULEY E, 1988, ANN RHEUM DIS, V47, P702, DOI 10.1136-ard.47.8.702; Cervera R, 2002, ARTHRITIS RHEUM, V46, P1019, DOI 10.1002-art.10187; CHAMPION RH, 1960, P ROY SOC MED, V53, P961; DEVOS J, 1992, DERMATOLOGY, V185, P296; Ehrmann S, 1907, WIEN MED WOCHENSCHR, V57, P777; ENGLERT HJ, 1989, AM J MED, V87, P408; Frances C, 1999, MEDICINE, V78, P209, DOI 10.1097-00005792-199907000-00001; Frances C, 2005, ARTHRITIS RHEUM, V52, P1785, DOI 10.1002-art.21041; Frances C, 2000, J AUTOIMMUN, V15, P139, DOI 10.1006-jaut.2000.0418; Gibbs MB, 2005, J AM ACAD DERMATOL, V52, P1009, DOI 10.1016-j.jaad.2004.11.051; HUGHES GRV, 1984, CLIN EXP DERMATOL, V9, P535, DOI 10.1111-j.1365-2230.1984.tb00856.x; Hughes GRV, 1999, ISRAEL MED ASSOC J, V1, P100; HUGHES GRV, 1983, BRIT MED J, V287, P1088; Hughes GRV, 2003, ANN RHEUM DIS, V62, P1127, DOI 10.1136-ard.2003.006163; KALASHNIKOVA LA, 1990, NEUROLOGY, V40, P464; Karassa FB, 2000, QJM-MON J ASSOC PHYS, V93, P169, DOI 10.1093-qjmed-93.3.169; KESTER S, 1992, ANN EMERG MED, V21, P207, DOI 10.1016-S0196-0644(05)80168-4; Khamashta MA, 2000, J AUTOIMMUN, V15, P249, DOI 10.1006-jaut.2000.0421; Kraemer M, 2005, J NEUROL, V252, P1155, DOI 10.1007-s00415-005-0967-9; LEVINE SR, 1988, NEUROLOGY, V38, P798; Lopez-Pedrera C, 2006, ARTHRITIS RHEUM, V54, P301, DOI 10.1002-art.21549; LUBACH D, 1990, J AM ACAD DERMATOL, V22, P633, DOI 10.1016-0190-9622(90)70087-X; MCHUGH NJ, 1988, ANN RHEUM DIS, V47, P110, DOI 10.1136-ard.47.2.110; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111-j.1538-7836.2006.01753.x; Piette WW, 2000, BRIT J DERMATOL, V142, P1080, DOI 10.1046-j.1365-2133.2000.03590.x; Sangle S, 2005, ANN RHEUM DIS, V64, P147, DOI 10.1136-ard.2004.020743; Sangle SR, 2003, ANN RHEUM DIS, V62, P999, DOI 10.1136-ard.62.10.999; Sangle SR, 2005, RHEUMATOLOGY, V44, P372, DOI 10.1093-rheumatolgy-keh490; Sepp N., 2003, DERMATOLOGY, P1651; SEPP N, 1995, AM J SURG PATHOL, V19, P448, DOI 10.1097-00000478-199504000-00006; SHEALY CN, 1970, J AMER MED ASSOC, V212, P1522; SNEDDON IB, 1965, BRIT J DERMATOL, V77, P180, DOI 10.1111-j.1365-2133.1965.tb14628.x; Tietjen GE, 2002, HEADACHE, V42, P352, DOI 10.1046-j.1526-4610.2002.02106.x; Toubi E, 2005, CLIN EXP RHEUMATOL, V23, P499; WEINSTEIN C, 1987, ARCH DERMATOL, V123, P596, DOI 10.1001-archderm.123.5.596; WEST SG, 1995, AM J MED, V99, P153, DOI 10.1016-S0002-9343(99)80135-1; Wohlrab J, 2001, BRIT J DERMATOL, V145, P285, DOI 10.1046-j.1365-2133.2001.04348.x; ZELGER B, 1993, ARCH DERMATOL, V129, P437, DOI 10.1001-archderm.129.4.437; ZELGER B, 1992, HUM PATHOL, V23, P668, DOI 10.1016-0046-8177(92)90323-U40292
The use of sildenafil in pediatric Takayasu arteritis
No full text[No abstract available]Kumana CR, 2004, ANN RHEUM DIS, V63, P1522, DOI 10.1136-ard.2003.015677; Lichtenstein JR, 2003, ARTHRITIS RHEUM, V48, P282, DOI 10.1002-art.1062833
Livedo racemosa: A striking dermatological sign for the antiphospholipid syndrome
No full text[No abstract available]Amengual O, 2003, RHEUMATOLOGY, V42, P1029, DOI 10.1093-rheumatology-keg273; Asherson RA, 2006, CLIN EXP RHEUMATOL, V24, pS46; ASHERSON RA, 1989, BRIT J DERMATOL, V120, P215; BAGULEY E, 1988, ANN RHEUM DIS, V47, P702, DOI 10.1136-ard.47.8.702; Cervera R, 2002, ARTHRITIS RHEUM, V46, P1019, DOI 10.1002-art.10187; CHAMPION RH, 1960, P ROY SOC MED, V53, P961; DEVOS J, 1992, DERMATOLOGY, V185, P296; Ehrmann S, 1907, WIEN MED WOCHENSCHR, V57, P777; ENGLERT HJ, 1989, AM J MED, V87, P408; Frances C, 1999, MEDICINE, V78, P209, DOI 10.1097-00005792-199907000-00001; Frances C, 2005, ARTHRITIS RHEUM, V52, P1785, DOI 10.1002-art.21041; Frances C, 2000, J AUTOIMMUN, V15, P139, DOI 10.1006-jaut.2000.0418; Gibbs MB, 2005, J AM ACAD DERMATOL, V52, P1009, DOI 10.1016-j.jaad.2004.11.051; HUGHES GRV, 1984, CLIN EXP DERMATOL, V9, P535, DOI 10.1111-j.1365-2230.1984.tb00856.x; Hughes GRV, 1999, ISRAEL MED ASSOC J, V1, P100; HUGHES GRV, 1983, BRIT MED J, V287, P1088; Hughes GRV, 2003, ANN RHEUM DIS, V62, P1127, DOI 10.1136-ard.2003.006163; KALASHNIKOVA LA, 1990, NEUROLOGY, V40, P464; Karassa FB, 2000, QJM-MON J ASSOC PHYS, V93, P169, DOI 10.1093-qjmed-93.3.169; KESTER S, 1992, ANN EMERG MED, V21, P207, DOI 10.1016-S0196-0644(05)80168-4; Khamashta MA, 2000, J AUTOIMMUN, V15, P249, DOI 10.1006-jaut.2000.0421; Kraemer M, 2005, J NEUROL, V252, P1155, DOI 10.1007-s00415-005-0967-9; LEVINE SR, 1988, NEUROLOGY, V38, P798; Lopez-Pedrera C, 2006, ARTHRITIS RHEUM, V54, P301, DOI 10.1002-art.21549; LUBACH D, 1990, J AM ACAD DERMATOL, V22, P633, DOI 10.1016-0190-9622(90)70087-X; MCHUGH NJ, 1988, ANN RHEUM DIS, V47, P110, DOI 10.1136-ard.47.2.110; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111-j.1538-7836.2006.01753.x; Piette WW, 2000, BRIT J DERMATOL, V142, P1080, DOI 10.1046-j.1365-2133.2000.03590.x; Sangle S, 2005, ANN RHEUM DIS, V64, P147, DOI 10.1136-ard.2004.020743; Sangle SR, 2003, ANN RHEUM DIS, V62, P999, DOI 10.1136-ard.62.10.999; Sangle SR, 2005, RHEUMATOLOGY, V44, P372, DOI 10.1093-rheumatolgy-keh490; Sepp N., 2003, DERMATOLOGY, P1651; SEPP N, 1995, AM J SURG PATHOL, V19, P448, DOI 10.1097-00000478-199504000-00006; SHEALY CN, 1970, J AMER MED ASSOC, V212, P1522; SNEDDON IB, 1965, BRIT J DERMATOL, V77, P180, DOI 10.1111-j.1365-2133.1965.tb14628.x; Tietjen GE, 2002, HEADACHE, V42, P352, DOI 10.1046-j.1526-4610.2002.02106.x; Toubi E, 2005, CLIN EXP RHEUMATOL, V23, P499; WEINSTEIN C, 1987, ARCH DERMATOL, V123, P596, DOI 10.1001-archderm.123.5.596; WEST SG, 1995, AM J MED, V99, P153, DOI 10.1016-S0002-9343(99)80135-1; Wohlrab J, 2001, BRIT J DERMATOL, V145, P285, DOI 10.1046-j.1365-2133.2001.04348.x; ZELGER B, 1993, ARCH DERMATOL, V129, P437, DOI 10.1001-archderm.129.4.437; ZELGER B, 1992, HUM PATHOL, V23, P668, DOI 10.1016-0046-8177(92)90323-U40292
Refractory polymyositis responding to infliximab [6]
No full text[No abstract available]Labioche I, 2004, RHEUMATOLOGY, V43, P531, DOI 10.1093-rheumatology-keh07927191
An overview of familial Mediterranean fever with emphasis on pyrin and colchicine
No full textFamilial Mediterranean fever (FMF) is the earliest known autoinflammatory disease, characterized by symptoms such as arthritis, peritonitis, pleuritis, erysipelas-like erythema, and most importantly amyloidosis. This disease is very common in populations of the Mediterranean area, and due to its high carrier frequency and occurrence rate in these populations, it has been the focus of much research work. Such research has allowed greater insights into the genetics of FMF, leading to the discovery of the responsible gene in 1997 and the determination of mutations and their effect on the phenotype of patients, as well as the interactions and roles of the pyrin protein, which seems to have various roles in regulation of innate immunity, inflammation, and apoptosis. Colchicine has been used as preventive treatment since 1972, and recent studies have allowed the determination of its mode of action.
An overview of familial Mediterranean fever with emphasis on pyrin and colchicine
No full textFamilial Mediterranean fever (FMF) is the earliest known autoinflammatory disease, characterized by symptoms such as arthritis, peritonitis, pleuritis, erysipelas-like erythema, and most importantly amyloidosis. This disease is very common in populations of the Mediterranean area, and due to its high carrier frequency and occurrence rate in these populations, it has been the focus of much research work. Such research has allowed greater insights into the genetics of FMF, leading to the discovery of the responsible gene in 1997 and the determination of mutations and their effect on the phenotype of patients, as well as the interactions and roles of the pyrin protein, which seems to have various roles in regulation of innate immunity, inflammation, and apoptosis. Colchicine has been used as preventive treatment since 1972, and recent studies have allowed the determination of its mode of action.
Endocrinologic manifestations of the antiphospholipid syndrome
No full textOur objective was to study the endocrinologic manifestations of the antiphospholipid syndrome (APS). We reviewed the medical literature from 1968 until 2005 using MEDLINE and the key words: APS, anticardiolipin antibodies, lupus anticoagulant, antiphospholipid antibodies, adrenal, thyroid, parathyroid, pituitary, diabetes, ovaries and testes. Adrenal insufficiency is the most common endocrinologic manifestation and can be the presenting symptom of APS. In patients with autoimmune thyroid disease circulating aPL have been detected. However, no clinical manifestations of APS have been described. A few cases of hypopituitarism have been reported, including a case of Sheehan's syndrome. aPL has been detected in the sera of diabetic patients, probably associated with some macroangiopathic complications. Finally only very few cases of ovarian and testicular involvement have been reported. The adrenals are the most commonly involved glands in the APS. Clinicians should keep a high index of suspicion for adrenal insufficiency in patients with APS. © 2006 SAGE Publications.Andre M, 1998, ANN RHEUM DIS, V57, P257, DOI 10.1136-ard.57.4.257; Andre M, 2004, ARTHRITIS RHEUM, V50, P183, DOI 10.1002-art.11435; ARNASON JA, 1995, SEMIN ARTHRITIS RHEU, V25, P109, DOI 10.1016-S0049-0172(95)80024-7; Asherson RA, 2001, MEDICINE, V80, P355, DOI 10.1097-00005792-200111000-00002; Asherson RA, 1998, MEDICINE, V77, P195, DOI 10.1097-00005792-199805000-00005; ASHERSON RA, 1989, J RHEUMATOL, V16, P378; ASHERSON RA, 1992, ANN RHEUM DIS, V51, P495, DOI 10.1136-ard.51.4.495; ASHERSON RA, 1991, J RHEUMATOL, V18, P1; BAETHGE BA, 1988, J CLIN ENDOCR METAB, V66, P485; Berneis K, 2003, EUR J HAEMATOL, V71, P299, DOI 10.1034-j.1600-0609.2003.00145.x; BUSKILA D, 1995, J AUTOIMMUN, V8, P415, DOI 10.1006-jaut.1995.0033; CARETTE S, 1989, ANN RHEUM DIS, V48, P430, DOI 10.1136-ard.48.5.430; Cervera R, 1997, CLIN EXP RHEUMATOL, V15, P361; d'Annunzio G, 1998, J PEDIATR ENDOCR MET, V11, P21; EICHNER HL, 1973, AM J MED, V55, P700, DOI 10.1016-0002-9343(73)90194-0; Espinosa G, 2003, MEDICINE, V82, P106, DOI 10.1097-00005792-200303000-00005; Fauchais AL, 2004, LUPUS, V13, P245, DOI 10.1191-0961203304lu1006oa; Fernandez Rosado E, 2004, ARCH ESPAN UROL, V57, P707; FOX B, 1976, J PATHOL, V119, P65, DOI 10.1002-path.1711190202; GERNER P, 2005, THROMB J, V3, P6, DOI 10.1186-1477-9560-3-6; Gin H, 2002, CLIN CHEM LAB MED, V40, P604, DOI 10.1515-CCLM.2002.104; Gobel U, 2002, NEPHROL DIAL TRANSPL, V17, P516, DOI 10.1093-ndt-17.3.516; GROTTOLO A, 1988, HAEMATOLOGICA, V73, P517; HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001-archinte.146.11.2153; HENDRA TJ, 1989, POSTGRAD MED J, V65, P140; Hofbauer LC, 1996, J RHEUMATOL, V23, P1435; HUGHES GRV, 1986, J RHEUMATOL, V13, P486; HUGHES GRV, 1983, BRIT MED J, V287, P1088; Ikeda K, 2000, RHEUMATOLOGY, V39, P447, DOI 10.1093-rheumatology-39.4.447; JEDRYKAGORAL A, 1992, ANN RHEUM DIS, V51, P889, DOI 10.1136-ard.51.7.889; Khamashta MA, 2004, AUTOIMMUNITY, V37, P309, DOI 10.1080-08916930410001708706; Leanos A, 1998, LUPUS, V7, P398, DOI 10.1191-096120398678920280; Leder AN, 2001, LUPUS, V10, P370, DOI 10.1191-096120301669209574; Marie I, 1997, ANN RHEUM DIS, V56, P567, DOI 10.1136-ard.56.9.567; MARONGIU F, 1991, THROMB RES, V64, P745, DOI 10.1016-0049-3848(91)90074-7; Nabriski D, 2000, AM J HEMATOL, V64, P73, DOI 10.1002-(SICI)1096-8652(200005)64:173::AID-AJH143.0.CO;2-U; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056-NEJM199610173351607; Osundeko O, 2001, Endocr Pract, V7, P181; PAGGI A, 1994, CLIN ENDOCRINOL, V40, P329; Pandolfi C, 1997, Minerva Endocrinol, V22, P103; PAPADOPOULOS KI, 1995, J INTERN MED, V238, P175; Presotto F, 2005, EUR J ENDOCRINOL, V153, P507, DOI 10.1530-eje.1.02002; RAO RH, 1989, ANN INTERN MED, V110, P227; Ringkananon Usanee, 2005, Journal of the Medical Association of Thailand, V88, P534; Sefer S, 2001, CROAT MED J, V42, P679; Takahashi A, 2002, J DERMATOL, V29, P776; Takebayashi K, 2003, AM J MED SCI, V325, P41, DOI 10.1097-00000441-200301000-00009; Toubi E, 1997, J RHEUMATOL, V24, P1451; Vlot AJ, 2001, LANCET, V358, P382, DOI 10.1016-S0140-6736(01)05559-3; Walker SE, 2000, RHEUM DIS CLIN N AM, V26, P713, DOI 10.1016-S0889-857X(05)70166-6; WALZ B, 1990, J RHEUMATOL, V17, P83615141
Response of deep cutaneous vasculitis to infliximab [2]
No full text[No abstract available]Mang R, 2004, J AM ACAD DERMATOL, V51, P321, DOI 10.1016-j.jaad.2004.01.003; Uthman I, 2004, SEMIN ARTHRITIS RHEU, V33, P422, DOI 10.1016-j.semarthrit.2003.12.005; Uthman I, 2004, CURR OPIN PHARMACOL, V4, P177, DOI 10.1016-j.coph.2003.11.00413101
- …
